Raptor sinks on Phase IIb pediatric NASH miss

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) fell $4.51 (37%) to $7.52 after RP103 missed its primary endpoint in the Phase IIb CyNCh trial to treat nonalcoholic steatohepatitis (NASH) in children ages 8-17. Raptor does not plan to advance the NASH program.

Patients receiving daily doses of the cysteamine bitartrate delayed-release capsules for 52 weeks failed to show a two-point decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) and also failed to show no worsening of fibrosis (p=0.34). ...